



ASX Announcement and Media Release

9 February, 2017

SciGen Ltd

RESIGNATION AND APPOINTMENT OF CEO

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) wishes to advise that Dr. James Kim, the Company’s Chief Executive Officer (“CEO”) and Director, has tendered his resignation from both positions in the Company for personal reasons, effectively immediately.

SciGen is pleased to announce that Mr. Ashley Morris has been appointed as the new CEO of the Company

Dr. Marek Dziki, the Company’s Chairman, said that he is delighted at the appointment of Mr. Morris as CEO. Mr. Morris has over 30 years’ experience within the pharmaceutical industry in the Asia Pacific. He is ideally suited to lead SciGen’s growth initiatives and drive the transformation process.

Mr. Morris has a B.A. Hons. in Politics & Economics from Nottingham University. From 2010 to 2013, Mr. Morris was the Managing Director of Bausch & Lomb covering Asean countries. From 2004 to 2009 he was with Schering-Plough starting as Area Director for South Asia and progressed to General Manager for Malaysia and Singapore. From 2001 to 2003, he was the Vice President for South Asia in Pharmacia. From 1978 to 2001, he held several positions in other Pharmaceutical companies such as Beecham, Farmitalia Carlo Erba, Pharmacia Asia and Pharmacia Philippines.

A summary of the key terms of Mr. Morris’ employment is attached.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster

entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China and Philippines, distribution channels in China, India, Malaysia, Myanmar, Pakistan, Thailand and Indonesia and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Adam Polonek SciGen Ltd +65 6779 6638

Summary of Key Employment Terms for Ashley Morris
CEO

1	Effective Date	9 February 2017
2	Term of Contract	3 years with provision for extension of the Term to be agreed upon by the parties
3	Remuneration	(1) Fixed <ul style="list-style-type: none"> • Base Salary of SGD 270,000 per annum • Transport Allowances of SGD 15,000 per annum
		(2) Variable <ul style="list-style-type: none"> • 10% to 50% of Base Salary upon achievement of milestone achievements set by the Board and agreed thereto by Mr. Morris
4	Benefits	Provident fund contributions, Insurance coverage, Medical and Dental expenses will be in accordance to the local regulations and Company's schemes
5	Notice Period	For termination without cause, either party to give to the other at least 3 months prior written notice
6	Restrictive Activities	Contract provides for restrictive covenants of 6 months non-competition and 12 months no-solicitation